Monoclonal Antibody-based Candidate Therapeutics Against HIV Type 1

Overview

Journal AIDS Res Hum Retroviruses

Publisher Mary Ann Liebert

Specialty Infectious Diseases

Date 2011 Aug 11

PMID 21827278

Citations 11

Authors

Weizao Chen

Dimiter S Dimitrov

Affiliations

Soon will be listed here.

Abstract

Treatment of HIV-1 infection has been highly successful with small molecule drugs. However, resistance still develops. In addition, long-term use can lead to toxicity with unpredictable effects on health. Finally, current drugs do not lead to HIV-1 eradication. The presence of the virus leads to chronic inflammation, which can result in increased morbidity and mortality after prolonged periods of infection. Monoclonal antibodies (mAbs) have been highly successful during the past two decades for therapy of many diseases, primarily cancers and immune disorders. They are relatively safe, especially human mAbs that have evolved in humans at high concentrations to fight diseases and long-term use may not lead to toxicities. Several broadly neutralizing mAbs (bnmAbs) against HIV-1 can protect animals but are not effective when used for therapy of an established infection. We have hypothesized that HIV-1 has evolved strategies to effectively escape neutralization by full-size antibodies in natural infections but not by smaller antibody fragments. Therefore, a promising direction of research is to discover and exploit antibody fragments as potential candidate therapeutics against HIV-1. Here we review several bnmAbs and engineered antibody domains (eAds), their in vitro and in vivo antiviral efficacy, mechanisms used by HIV-1 to escape them, and strategies that could be effective to develop more powerful mAb-based HIV-1 therapeutics.

Citing Articles

Monoclonal antibodies: From magic bullet to precision weapon.

Aboul-Ella H, Gohar A, Ali A, Ismail L, Mahmoud A, Elkhatib W Mol Biomed. 2024; 5(1):47.

PMID: 39390211 PMC: 11467159. DOI: 10.1186/s43556-024-00210-1.

Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS.

Joseph J, Sandel G, Kulkarni R, Alatrash R, Herrera B, Jain P Pathogens. 2024; 13(1).

PMID: 38251321 PMC: 10821063. DOI: 10.3390/pathogens13010014.

Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.

Tatsing Foka F, Tumelo Mufhandu H Viruses. 2023; 15(8).

PMID: 37632074 PMC: 10458198. DOI: 10.3390/v15081732.

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.

Gartland M, Zhou N, Stewart E, Pierce A, Clark A, Ackerman P J Antimicrob Chemother. 2020; 76(3):648-652.

PMID: 33241285 PMC: 7879148. DOI: 10.1093/jac/dkaa474.

The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases.

Pour P, Fakhri S, Asgary S, Farzaei M, Echeverria J Front Pharmacol. 2019; 10:1207.

PMID: 31787892 PMC: 6856223. DOI: 10.3389/fphar.2019.01207.

References

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C . Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005; 11(6):615-22. DOI: 10.1038/nm1244. View

Haynes B, Fleming J, St Clair E, Katinger H, Stiegler G, Kunert R . Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005; 308(5730):1906-8. DOI: 10.1126/science.1111781. View

Li A, Katinger H, Posner M, Cavacini L, Zolla-Pazner S, Gorny M . Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol. 1998; 72(4):3235-40. PMC: 109792. DOI: 10.1128/JVI.72.4.3235-3240.1998. View

Jekle A, Chow E, Kopetzki E, Ji C, Yan M, Nguyen R . CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency. Antiviral Res. 2009; 83(3):257-66. DOI: 10.1016/j.antiviral.2009.06.005. View

Kwong P, Wyatt R, Robinson J, Sweet R, Sodroski J, Hendrickson W . Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998; 393(6686):648-59. PMC: 5629912. DOI: 10.1038/31405. View

Jain R, Baxter L . Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988; 48(24 Pt 1):7022-32. View

Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

Pejchal R, Gach J, Brunel F, Cardoso R, Stanfield R, Dawson P . A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol. 2009; 83(17):8451-62. PMC: 2738203. DOI: 10.1128/JVI.00685-09. View

Lagenaur L, Villarroel V, Bundoc V, Dey B, Berger E . sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology. 2010; 7:11. PMC: 2843639. DOI: 10.1186/1742-4690-7-11. View

10.

Chen W, Dimitrov D . Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS. 2009; 4(2):112-7. PMC: 2762325. DOI: 10.1097/COH.0b013e328322f95e. View

11.

Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N . Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996; 70(2):1100-8. PMC: 189917. DOI: 10.1128/JVI.70.2.1100-1108.1996. View

12.

Zhang M, Choudhry V, Sidorov I, Tenev V, Vu B, Choudhary A . Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods. 2006; 317(1-2):21-30. PMC: 1805821. DOI: 10.1016/j.jim.2006.09.016. View

13.

Choudhry V, Zhang M, Harris I, Sidorov I, Vu B, Dimitrov A . Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun. 2006; 348(3):1107-15. PMC: 2268024. DOI: 10.1016/j.bbrc.2006.07.163. View

14.

Cavacini L, Samore M, Gambertoglio J, Jackson B, Duval M, Wisnewski A . Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses. 1998; 14(7):545-50. DOI: 10.1089/aid.1998.14.545. View

15.

Baba T, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S . Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000; 6(2):200-6. DOI: 10.1038/72309. View

16.

Li A, Baba T, Sodroski J, Zolla-Pazner S, Gorny M, Robinson J . Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses. 1997; 13(8):647-56. DOI: 10.1089/aid.1997.13.647. View

17.

Huskens D, Van Laethem K, Vermeire K, Balzarini J, Schols D . Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology. 2006; 360(2):294-304. DOI: 10.1016/j.virol.2006.10.027. View

18.

Choudhry V, Zhang M, Sidorov I, Louis J, Harris I, Dimitrov A . Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology. 2007; 363(1):79-90. PMC: 2696119. DOI: 10.1016/j.virol.2007.01.015. View

19.

Dey B, Del Castillo C, Berger E . Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol. 2003; 77(5):2859-65. PMC: 149752. DOI: 10.1128/jvi.77.5.2859-2865.2003. View

20.

Ichiyoshi Y, Casali P . Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J Exp Med. 1994; 180(3):885-95. PMC: 2191637. DOI: 10.1084/jem.180.3.885. View